Correlation between lipidic content and arterial-wall plaque burden: A Lipid Rich Plaque study sub-analysis.


Journal

International journal of cardiology
ISSN: 1874-1754
Titre abrégé: Int J Cardiol
Pays: Netherlands
ID NLM: 8200291

Informations de publication

Date de publication:
01 11 2022
Historique:
received: 07 12 2021
revised: 21 06 2022
accepted: 12 07 2022
pubmed: 17 7 2022
medline: 14 9 2022
entrez: 16 7 2022
Statut: ppublish

Résumé

Large plaque burden (PB) has been linked to adverse coronary events. We sought to assess the correlation between lipidic content and arterial PB within the Lipid Rich Plaque (LRP) study. This analysis included 1269 patients and 5743 coronary segments with both evaluable Lipid Core Burden Index (maxLCBI NC-MACE for segment cohorts in the most vulnerable quadrant of maxLCBI Coronary segments with high lipid content but no measurable PB were still associated with events at 2 years. NC-MACE vulnerability increased as the lipidic content and PB increased, with the highest incidence within segments having maxLCBI The Lipid-Rich Plaque Study (LRP), NCT02033694, https://clinicaltrials.gov/ct2/show/NCT02033694.

Sections du résumé

BACKGROUND
Large plaque burden (PB) has been linked to adverse coronary events. We sought to assess the correlation between lipidic content and arterial PB within the Lipid Rich Plaque (LRP) study.
METHODS
This analysis included 1269 patients and 5743 coronary segments with both evaluable Lipid Core Burden Index (maxLCBI
RESULTS
NC-MACE for segment cohorts in the most vulnerable quadrant of maxLCBI
CONCLUSIONS
Coronary segments with high lipid content but no measurable PB were still associated with events at 2 years. NC-MACE vulnerability increased as the lipidic content and PB increased, with the highest incidence within segments having maxLCBI
CLINICAL TRIAL REGISTRATION
The Lipid-Rich Plaque Study (LRP), NCT02033694, https://clinicaltrials.gov/ct2/show/NCT02033694.

Identifiants

pubmed: 35842005
pii: S0167-5273(22)01092-0
doi: 10.1016/j.ijcard.2022.07.024
pii:
doi:

Substances chimiques

Lipids 0

Banques de données

ClinicalTrials.gov
['NCT02033694']

Types de publication

Clinical Study Journal Article

Langues

eng

Sous-ensembles de citation

IM

Pagination

32-34

Informations de copyright

Copyright © 2022 Elsevier B.V. All rights reserved.

Auteurs

Rebecca Torguson (R)

The Zena and Michael A. Wiener Cardiovascular Institute, Icahn School of Medicine at Mount Sinai, New York, NY, USA.

Gary S Mintz (GS)

Section of Interventional Cardiology, MedStar Washington Hospital Center, Washington, DC, USA.

Brian C Case (BC)

Section of Interventional Cardiology, MedStar Washington Hospital Center, Washington, DC, USA.

Carlo Di Mario (C)

Structural Interventional Cardiology, Department of Clinical & Experimental Medicine, Careggi University Hospital, Florence, Italy.

Cheng Zhang (C)

Section of Interventional Cardiology, MedStar Washington Hospital Center, Washington, DC, USA.

Corey Shea (C)

Section of Interventional Cardiology, MedStar Washington Hospital Center, Washington, DC, USA.

Hector M Garcia-Garcia (HM)

Section of Interventional Cardiology, MedStar Washington Hospital Center, Washington, DC, USA.

Ron Waksman (R)

Section of Interventional Cardiology, MedStar Washington Hospital Center, Washington, DC, USA. Electronic address: ron.waksman@medstar.net.

Articles similaires

[Redispensing of expensive oral anticancer medicines: a practical application].

Lisanne N van Merendonk, Kübra Akgöl, Bastiaan Nuijen
1.00
Humans Antineoplastic Agents Administration, Oral Drug Costs Counterfeit Drugs

Smoking Cessation and Incident Cardiovascular Disease.

Jun Hwan Cho, Seung Yong Shin, Hoseob Kim et al.
1.00
Humans Male Smoking Cessation Cardiovascular Diseases Female
Humans United States Aged Cross-Sectional Studies Medicare Part C
1.00
Humans Yoga Low Back Pain Female Male

Classifications MeSH